Babafemi Taiwo - Concepedia

Author

Babafemi Taiwo

Also Known As

Adesola Ogunniyi, Aliou Sylla, Anne Lachiewicz, Azaria Diergaardt, B O Taiwo, B Taiwo, B. O. Taiwo, B. Taiwo, B.O. Taiwo, BABAFEMI O. TAIWO

235

Publications

7.3K

Citations

H-Index

Concepts

All Affiliations

Northwestern University Harvard University University of North Carolina at Chapel Hill Center for Global Health University of Ibadan

About

Babafemi Taiwo is an author at Northwestern University specializing in medicine, hiv, and epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	791
2	Public Health	7	7	336
3	Engineering	1	1	14
4	Health Sciences	1	1	14
5	Social Sciences	1	1	12

Babafemi Taiwo

Publications

4.9K

Citations

H-Index

Page 1

	Year	Citations
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 André C. Kalil, Thomas F. Patterson, Aneesh K. Mehta, New England Journal of Medicine	2020	1.9K
Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262) Babafemi Taiwo, Lu Zheng, Sébastien Gallien, AIDS	2011	147
Antiretroviral Drug Resistance in HIV-1–Infected Patients Experiencing Persistent Low-Level Viremia During First-Line Therapy Babafemi Taiwo, Sébastien Gallien, Evgenia Aga, The Journal of Infectious Diseases Antiretroviral Drug ResistanceFirst-line TherapyImmunologyPersistent Low-level ViremiaPharmacotherapy	2011	144
Clinical Outcomes of Adolescents and Young Adults in Adult HIV Care Patrick Ryscavage, Evan J. Anderson, Sarah H. Sutton, JAIDS Journal of Acquired Immune Deficiency Syndromes Poor Clinical OutcomesFamily MedicineYoung AdultsAdolescent Behavioral HealthAdolescence	2011	141
Significance and Clinical Management of Persistent Low-Level Viremia and Very-Low-Level Viremia in HIV-1-Infected Patients Patrick Ryscavage, Sean G. Kelly, Jonathan Z. Li, Antimicrobial Agents and Chemotherapy	2014	133
Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients J A Otegbayo, Babafemi Taiwo, Titilola S. Akingbola, Annals of Hepatology	2008	129
Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4×: a phase 2 randomised, double-blind, placebo-controlled trial Richard B. Pollard, Jürgen K. Rockstroh, Giuseppe Pantaleo, The Lancet Infectious Diseases	2014	107
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)–infected Participants With HIV-1 RNA <500000 Copies/mL Babafemi Taiwo, Lu Zheng, Andrei Ștefănescu, Clinical Infectious Diseases	2017	94
Frailty is strongly associated with increased risk of recurrent falls among older HIV-infected adults Katherine Tassiopoulos, Mona Abdo, Kunling Wu, AIDS	2017	85
Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial Babafemi Taiwo, Vincent C. Marconi, Baiba Berzins, Clinical Infectious Diseases	2017	84

Page 1